Dow Jones received a payment from EQS/DGAP to publish this press release.
DGAP-Media / 2019-03-28 / 09:00
*MagForce AG: Official opening ceremony for NanoTherm Treatment Center at
the Independent Public Clinical Hospital No. 4 in Lublin, Poland *
? *Celebratory ceremony will mark official opening of the new NanoTherm
treatment center for brain tumors at the Independent Public Clinical
Hospital No. 4 in Lublin*
? *First hospital oustide of Germany begins treatment of brain tumor
patients with Magforce's NanoTherm therapy *
? *Faster access to therapy after diagnosis adressing high unmet medical
need in Poland*
*Lublin, Poland, March 28, 2019 - *MagForce AG (Frankfurt, Scale, XETRA:
MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of
nanomedicine focused on oncology, is pleased to announce the official
opening of the new NanoTherm treatment center for brain tumors at the
Independent Public Clinical Hospital No. 4 in Lublin ("Samodzielny Publiczny
Szpital Kliniczny Nr 4 w Lublinie", SPSK4), Poland.
The ribbon-cutting ceremony followed by an invitation-only reception will be
held on, April 3, 2019, in the presence of invited guests from government,
science, patient organisations and the press. The ceremony will be hosted by
Krzysztof Zuk, Mayor of the City of Lublin, as well as representatives from
MagForce and SPSK4.
The NanoTherm treatment center at SPSK4 will be headed by Prof. Dr. hab. n.
med. Tomasz Trojanowski, Head and Chairman of the Neurosurgery and
Paediatric Neurosurgery Departments, State Consultant in Neurosurgery and a
member of the Scientific Advisory Board for the Minister of Health, together
with Prof. Dr. hab. n. med. Radoslaw Rola a new Head and Chairman of the
Neurosurgery and Paediatric Neurosurgery Departments in SPSK4 in Lublin.
*Bringing innovation to the patient: Access to new treatment options in
Poland remains a high unmet medical need *
According to estimates, every fourth inhabitant of Poland is diagnosed with
cancer during their life, and every fifth will die from it. Although recent
years have brought about rapid progress in the knowledge of pathomechanisms
underlying each cancer, and cancer itself, contributing to many new drugs
and therapies being launched onto the market, access to effective treatment
options in Poland remain limited. As a result, the average Pole has a lower
chance to survive 5 years with cancer compared to citizens of other European
countries.[1]
SPSK4 in Lublin is the first hospital outside of Germany to offer MagForce's
NanoTherm therapy for the treatment of brain tumor patients. The cooperation
agreement, announced in June of 2018, will provide brain cancer patients
from surrounding areas with faster access to the therapy after diagnosis
whilst allowing Polish patients to be treated with NanoTherm therapy in
their home country. Due to the aggressive nature of glioblastoma, timely
availability is a decisive factor in the treatment of brain tumors as there
is only a narrow window for patients to receive treatment.
"We are pleased to work with such a strong partner as the SPSK4 to bring
NanoTherm therapy to Poland. We see a huge need for additional therapeutic
options for the treatment of brain tumors in this country. It is underlined
by the fact, that more than 50% of all patient inquiries who could qualify
for NanoTherm therapy come from Poland, and that number continues to
increase. Therefore, the opening of this NanoTherm treatment center is a
great success for MagForce and a chance for brain tumor patient to receive
an alternative treatment option. I am encouraged by the positive response we
have seen so far", *said Dr. Katarzyna Zarychta, Vice President Oncology
Market Development Europe, MagForce AG.*
The collaboration with Independent Public Clinical Hospital No. 4 in Lublin
will be supported by the efforts of the Alivia Cancer Foundation, Poland.
The Foundations's mission is to mobilize, empower and educate cancer
patients, as well as give them the tools and necessary means to make
decisions regarding their own health.
*Notes for editors: *
*The Role of NanoTherm Therapy in the Treatment of Brain Tumors*
NanoTherm therapy is a relatively new procedure for the focal treatment of
solid tumors. Summarised in simple terms: Magnetic nanoparticles are
introduced either directly into the tumor or into the resection cavity wall.
These particles are subsequently heated by an alternating magnetic field,
thus destroying the cancer cells.
Nanoparticles are tiny particles of iron oxide that are suspended - very
finely distributed - in water, having a diameter of approximately 15
nanometres - while one nanometer corresponds one millionth millimetre. As
soon as they are applied, they agglomerate and remain like an implant in the
tissue to be treated. An alternating magnetic field, which changes its
polarity up to 100,000 times per second, subsequently causes the particles
to generate heat.
Depending on the therapeutic temperatures reached in the tumor or in
individual remaining cancer cells in the resection cavity wall and the
length of treatment, cancer cells are thereby irreparably destroyed, or they
are weakened and made more sensitive to concomitant radiotherapy or
chemotherapy. The way in which the nanoparticles are applied is decided
individually by the attending neurosurgeon.
This new technology makes it possible to fight the tumor from the inside out
or to ensure that individual remaining tumor cells in the resection cavity
wall - which may be responsible for recurrence - can be fought and destroyed
after the surgical removal of the tumor. The surrounding healthy tissue is
spared since the particles remain at the site of application due to their
special surface structure.
*About Independent Public Clinical Hospital No. 4 in Lublin, Poland*
The Independent Public Clinical Hospital No. 4 in Lublin is the largest
hospital in Lublin Province, comprising 22 highly specialised clinics and
providing learning and research facilities for the Medical University in
Lublin. The hospital serves patients from Lublin province as well as from
other regions of the country and abroad. Over 1,600 patients receive surgery
yearly, and about 6,000 consultations are given in an outpatient
neurosurgical clinic.
In July 2010, due to high quality of the provided services and extensive
treatment and diagnosis facilities, by the decision of the Minister of
Health, the IPC Hospital no. 4 became a Trauma Centre for Lublin Province.
In 2012 the hospital became one of the few hospitals in Poland that own a
positron emission tomography scanner (PET).
*About MagForce AG and MagForce USA, Inc.*
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted
treatment of solid tumors through the intratumoral generation of heat via
activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices for
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and
NanoActivator are trademarks of MagForce AG in selected countries.
*For more information, please visit: www.magforce.com [1].
Get to know our Technology: video (You Tube) [2]
Stay informed and subscribe to our mailing list [3]*
_Disclaimer _
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
*Contact:*
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com
[1] Oncology patients' access to drug therapies in Poland in view of current
medical knowledge, Report March 2017:
https://www.alivia.org.pl/raport2017/ALIVIA_REPORT_EN_web.pdf [4]
End of Media Release
Issuer: MagForce AG
Key word(s): Health
2019-03-28 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt
(Scale), Stuttgart, Tradegate Exchange
EQS News ID: 792775
End of News DGAP Media
792775 2019-03-28
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=792775&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=792775&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=792775&site_id=vwd&application_name=news
(MORE TO FOLLOW) Dow Jones Newswires
March 28, 2019 04:00 ET (08:00 GMT)
